----
Current ValuationThe current P/E ratio is -4.76, above the reasonable range, cheaper than 0.38% of the time in the past 1 years, and the industry ranks 43/74, the industry Median --.
-4.76xP/E
$1.27Stock price
$-0.27Earnings per share
-4.76xP/E
Stock price$1.27Earnings per share$-0.27
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -6.11x
- Typical range
- -6.33x–-5.63x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
07142128
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
GHUSGuardant Health | -48.18x | 2.97% | $21.85B |
HIMSUSHims & Hers Health | -50.33x | 209.86% | $7.15B |
RDNTUSRadnet | -266.44x | 128.00% | $5.63B |
NEOUSNeogenomics | -40.12x | 64.43% | $2.08B |
WGSUSGeneDx | -17.90x | 359.59% | $1.90B |
AGLUSagilon health | -6.18x | 92.48% | $1.44B |
INNVUSInnovage | -492.13x | 2,301.70% | $1.25B |
OPKUSOpko Health | -14.13x | 25.99% | $1.03B |
LMRIUSLumexa Imaging | -37.00x | 145.51% | $1.03B |
CSTLUSCastle Biosciences | -51.55x | 52.61% | $1.00B |
FLGTUSFulgent Genetics | -7.00x | 42.64% | $590.75M |
GMRSUSGMR Solutions | -7.57x | 91.45% | $572.63M |
AONCUSAmerican Oncology Network | -- | -- | $372.75M |
PREUSPrenetics Global | -7.72x | 16.63% | $362.76M |
BDSXUSBiodesix | -9.77x | 42.77% | $271.16M |
GAMGUSGlobal Asset Management Group, Inc. | -382.76x | -- | $216.04M |
NAKAUSNakamoto | -0.35x | 102.50% | $147.81M |
CORBFUSGlobal Cord Blood Corporation | -- | -- | $127.35M |
AIRSUSAirSculpt Tech | -10.01x | 33.33% | $117.52M |
PARKUSPark Dental Partners | -27.25x | -- | $96.34M |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
